… Full field stimulus testing (FST) to assess sepofarsen patient response in Leber congenital amaurosis … phase 1b/2 trial, 11 LCA10 patients received intravitreal sepofarsen . The goal was to evaluate patient response to …
… Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber … presents the 12-month results of a phase 1b/2 trial of sepofarsen. Following the results presentation, Dr. Russell …
ARVO 2021 presentation by Stephen R. Russell from Iowa University on the Safety and efficacy of sepofarsen in the second treated eye in a Ph1b/2 extension trial in CEP290 mediated Leber Congenital Amaurosis type 10.
… Results of a phase 1b/2 trial of intravitreal (IVT) sepofarsen (QR-110) antisense oligonucleotide in Leber … Stephen Russel et al. Recognized with best poster award. Sepofarsen had a manageable safety profile and showed …
… ProQR Announces Publication in Nature Medicine for Sepofarsen in Leber Congenital Amaurosis 10 LEIDEN, … after a single treatment with antisense oligonucleotide sepofarsen: a case report ” describing durable vision …
… Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10 Study did not meet … 12. “Given the results observed in earlier studies of sepofarsen, the Illuminate trial results are unexpected and …
… Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets Agreement … based on commercial sales in the US and EU Divestment of sepofarsen and ultevursen supports ProQR’s strategic focus on …
… ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Top-line results expected H1 2022 Sepofarsen is a potential first-in-class RNA therapy for the …
… ProQR Announces Virtual Presentation of Phase 1/2 Sepofarsen Extension Trial Data at the Association for … from the Company’s Phase 1/2 InSight extension trial of sepofarsen and live Q&A session at the Association for …
… ProQR Announces Expert Perspectives Call on LCA10 and Sepofarsen Call on July 20 will include a snapshot from the ongoing InSight open-label extension study of sepofarsen, including preliminary second eye treatment data …
